Severe Adverse Drug Reactions in Psychiatric Inpatients Treated with Neuroleptics

Numerous studies compare side effects or adverse drug reactions (ADRs) of the various typical and newer atypical neuroleptics in patients with schizophrenia. However, these studies, as controlled randomized trials, represent an artificial setting of drug administration and do not easily relate to the ”real-life” setting of psychiatric treatment. In contrast, the AMSP drug safety program allows the monitoring of ADRs of all types of psychopharmacological agents in the naturalistic setting of routine clinical practice. In the present study, the data on neuroleptics acquired in the AMSP program from 1993 to 2000 are analyzed. In this period, 86,439 patients treated with at least one neuroleptic agent were monitored. In 1.1 % of the patients severe ADRs occurred. In contrast to the results from controlled trials, atypical neuroleptics caused more severe ADRs than did typical neuroleptics. This result was mainly caused by the high number of severe ADRs in patients treated with clozapine and concerned delirium and non-EPS neurological, gastrointestinal, hepatic, dermatological, hematological, and endocrinological ADRs. Atypical neuroleptics were found to be superior in EPS and urological ADRs. Excluding the data on clozapine, we found typical and atypical neuroleptics to be similar in the occurrence of severe ADRs, although the profiles differ between these two groups as well as between the single substances. Our findings provide valuable information on the type and frequency of ADRs in psychiatric practice, thus enabling differential indication of neuroleptics based not only on the efficacy and tolerability data of controlled trials but also on their differential ADR profile occurring in the ”real-life” setting of routine clinical treatment.

References

• 1 Barnes T R, McPhillips M A. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics.  J Psychiatry. 1999;  174 (Suppl 38) 34-42
• 2 Bender S, Olbrich H M, Fischer W, Hornstein C, Schoene W, Falkai P, Haarmann C, Berger M, Gastpar M. Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine.  Pharmacopsychiatry. 2003;  36 61-69
• 3 Bergemann N, Ehrig C h, Diebold K, Mundt C h, Einsiedel R v. Asymptomatic pancreatitis associated with clozapine.  Pharmacopsychiatry. 1999;  32 78-80
• 4 Caroff S N, Mann S C, Campbell E C, Sullivan K A. Movement disorders associated with atypical antipsychotic drugs.  J Clin Psychiatry. 2002;  63 (suppl 4) 12-19
• 5 Conley R R, Meltzer H Y. Adverse events related to olanzapine.  J Clin Psychiatry. 2000;  61 (suppl 8) 26-29
• 6 Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.  Br Med J. 2000;  321 1371-1376
• 7 Grohmann R, Hippius H, Helmchen H, Rüther E, Schmidt L G. The AMÜP study for drug surveillance in psychiatry - a summary of inpatient data.  Pharmacopsychiatry. 2004;  37 Suppl 1 S16-26
• 8 Grohmann R, Rüther E, Engel R R, Hippius H. Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: Methods and first results for tricyclic antidepressants and SSRI.  Pharmacopsychiatry. 1999;  32 21-28
• 9 Grohmann R, Rüther E, Schmidt L G. Unerwünschte Wirkungen von Psychopharmaka: Ergebnisse der AMÜP-Studie. Berlin Heidelberg New York; Springer 1994
• 10 Jaber M, Robinson S W, Missale C, Caron M C. Dopamine receptors and brain function.  Neuropharmacology. 1996;  35 1503-1519
• 11 Javitt D C. Treatment of negative and cognitive symptoms.  Curr Psychiatry Rep. 1999;  1 25-30
• 12 Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.  Annu Rev Med. 2001;  52 503-517
• 13 Kropp S, Grohmann R, Hauser U, Rüther E, Degner D. Hyperglycemia associated with antipsychotic treatment in a Multicenter Drug Safety Project.  Pharmacopsychiatry. 2004;  37 Suppl 1 S79-83
• 14 Kropp S, Ziegenbein M, Grohmann R, Engel R R, Degner D. Galactorrhea due to psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S84-88
• 15 Kurzthaler I, Fleischhacker W W. The clinical implications of weight gain in schizophrenia.  J Clin Psychiatry. 2001;  62 (suppl 7) 32-37
• 16 Lambert M, Graf Schimmelmann B, Karow A, Naber D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs - concepts, measurement and clinical relevance.  Pharmacopsychiatry. 2003;  36 Suppl 3 S181-190
• 17 Linka T, Dittmann-Balcar A, Grohmann R, Bender S. Assessment of sexual dysfunctions in schizophrenic in-patients with the AMSP drug safety program.  Schizophr Res. 2003;  60 (suppl 1) 361-362
• 18 Ng B, Postlethwaite A, Rollnik J. Peripheral oedema in patients taking olanzapine.  Int Clin Psychopharmacol. 2002;  18 57-58
• 19 Pinikahana J, Happell B, Taylor M, Keks N A. Exploring the complexity of compliance in schizophrenia.  Issues Ment Health Nurs. 2002;  23 513-528
• 20 Grohmann R, Engel R, Rüther E, Hippius H. The AMSP Drug Safety Program: Methods and Global Results.  Pharmacopsychiatry. 2004;  37 Suppl 1 S4-11
• 21 Schillervoort I, de Boer A, Herings R M, Roos R A, Jansen P A, Leufkens H G. Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.  Ann Pharmacother. 2001;  35 1659-1660
• 22 Schmid C, Grohmann R, Engel R R, Rüther E, Kropp S. Cardiac adverse effects associated with psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S65-69
• 23 Stübner S, Rustenbeck E, Grohmann R, Wagner G, Engel R, Neundörfer G, Möller H -J, Hippius H, Rüther E. Severe and uncommon involuntary movement disorders due to psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S54-64
• 24 Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig W -D, Wagner G, Müller-Oerlinghausen B, Möller H -J, Hippius H, Rüther E. Blood dyscrasias induced by psychotropic drugs.  Pharmacopsychiatry. 2004;  37 Suppl 1 S70-78
• 25 Wolstein J, Grohmann R, Rüther E, Hippius H. Antipsychotic drugs and venous thromboembolism.  Lancet. 2000;  356 252
• 26 Young J, Zonana H, Shepler L. Medication noncompliance in schizophrenia: codification and update.  Bull Am Acad Psychiatry Law. 1986;  14 105-122